Building the World’s First Dedicated Drug Discovery Platform Centered on Protein Motion

Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach as an integrated team focused on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. 

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

July 24, 2017
Relay Therapeutics Names Deborah Palestrant, Ph.D., Vice President of Corporate Development and Strategy

April 4, 2017
Relay Therapeutics Appoints Pharmaceutical Leader Sanjiv K. Patel, M.D. to President and Chief Executive Officer

September 14, 2016
Third Rock Ventures Launches Relay Therapeutics with $57 Million Series A Financing to Create Breakthrough Medicines Based on Protein Motion

Read More News

Associated Team Members

Alexis Borisy